<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Probi Ltd</title>
	<atom:link href="http://probi.se/en/feed/" rel="self" type="application/rss+xml" />
	<link>http://probi.se/en</link>
	<description></description>
	<lastBuildDate>Mon, 20 May 2013 07:26:57 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Annual General Meeting 2013</title>
		<link>http://probi.se/en/2013/04/24/annual-general-meeting-2013-2/</link>
		<comments>http://probi.se/en/2013/04/24/annual-general-meeting-2013-2/#comments</comments>
		<pubDate>Wed, 24 Apr 2013 15:17:20 +0000</pubDate>
		<dc:creator>sofie</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2463</guid>
		<description><![CDATA[2013-04-26 Read the full release here]]></description>
			<content:encoded><![CDATA[<p><strong>2013-04-26</strong></p>
<p><a href="http://probi.se/en/files/2013/04/2013-04-Probi-Pressmeddelande-Årsstämma_eng.pdf" target="_blank">Read the full release here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2013/04/24/annual-general-meeting-2013-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interim report January &#8211; March 2013</title>
		<link>http://probi.se/en/2013/04/24/interim-report-january-march-2013/</link>
		<comments>http://probi.se/en/2013/04/24/interim-report-january-march-2013/#comments</comments>
		<pubDate>Wed, 24 Apr 2013 09:25:47 +0000</pubDate>
		<dc:creator>sofie</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2454</guid>
		<description><![CDATA[2013-04-24 Good start to 2013 Read the full release here]]></description>
			<content:encoded><![CDATA[<p><strong>2013-04-24</strong></p>
<p><strong>Good start to 2013</strong></p>
<p><a href="http://probi.se/en/files/2013/04/Probi-Q1-2013-eng.pdf" target="_blank">Read the full release here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2013/04/24/interim-report-january-march-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Annual General Meeting 2013</title>
		<link>http://probi.se/en/2013/03/25/annual-general-meeting-2013/</link>
		<comments>http://probi.se/en/2013/03/25/annual-general-meeting-2013/#comments</comments>
		<pubDate>Mon, 25 Mar 2013 14:44:39 +0000</pubDate>
		<dc:creator>sofie</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2387</guid>
		<description><![CDATA[2013-03-25 The shareholders of Probi AB (publ) are hereby officially convened to the Annual General Meeting (AGM) which will be held on Wednesday 24 April 2013 at 3:00 p.m. at Elite Hotel, Ideon Gateway, Scheelevägen 27, Lund, Sweden. Intention to participate must be notified to the company no later than Thursday, 18 April 2013 at [...]]]></description>
			<content:encoded><![CDATA[<p><strong>2013-03-25</strong></p>
<p align="LEFT"><strong>The shareholders of Probi AB (publ) are hereby officially convened to the Annual General Meeting (AGM) which will be held on Wednesday 24 April 2013 at 3:00 p.m. at Elite Hotel, Ideon Gateway, Scheelevägen 27, Lund, Sweden. Intention to participate must be notified to the company no later than Thursday, 18 April 2013 at 4:00 p.m. (CET).</strong></p>
<p align="LEFT"><strong><a href="http://probi.se/en/files/2013/03/Kallelse-årsstämma-ENG.pdf" target="_blank">Read the entire Notice of the Annual General Meeting 2013 here</a></strong></p>
<h3></h3>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2013/03/25/annual-general-meeting-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Probi and NextFoods strengthen their GoodBelly® partnership in the USA</title>
		<link>http://probi.se/en/2013/02/19/probi-and-nextfoods-strengthen-their-goodbelly%c2%ae-partnership-in-the-usa/</link>
		<comments>http://probi.se/en/2013/02/19/probi-and-nextfoods-strengthen-their-goodbelly%c2%ae-partnership-in-the-usa/#comments</comments>
		<pubDate>Tue, 19 Feb 2013 08:25:28 +0000</pubDate>
		<dc:creator>sofie</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2378</guid>
		<description><![CDATA[2013-02-19 Probi and NextFoods strengthen their GoodBelly® partnership in the USA Probi and US food company NextFoods are strengthening their partnership on the North American market through a revised agreement which will run until 2020, with an option of further extension. This involves closer collaboration, a higher level of royalties for Probi starting from 1 [...]]]></description>
			<content:encoded><![CDATA[<p><strong>2013-02-19</strong></p>
<h3><strong>Probi and NextFoods strengthen their GoodBelly<sup>®</sup> partnership in the USA</strong></h3>
<p>Probi and US food company NextFoods are strengthening their partnership on the North American market through a revised agreement which will run until 2020, with an option of further extension. This involves closer collaboration, a higher level of royalties for Probi starting from 1 July 2014, and prominent placement on GoodBelly<sup>®</sup> packaging and in advertising of the Probi Digestis<sup>® </sup>brand.</p>
<p><a href="http://probi.se/en/files/2013/02/2013-02-Probi-release-NextFoods_eng.pdf" target="_blank">Read the full release here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2013/02/19/probi-and-nextfoods-strengthen-their-goodbelly%c2%ae-partnership-in-the-usa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Year-end Report 2012</title>
		<link>http://probi.se/en/2013/01/24/year-end-report-2012/</link>
		<comments>http://probi.se/en/2013/01/24/year-end-report-2012/#comments</comments>
		<pubDate>Thu, 24 Jan 2013 09:13:32 +0000</pubDate>
		<dc:creator>sofie</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2356</guid>
		<description><![CDATA[2013-01-24 Operating revenue exceeded MSEK 100 with continued healthy profitability Read the full release here]]></description>
			<content:encoded><![CDATA[<p><strong>2013-01-24</strong></p>
<h3><strong>Operating revenue exceeded MSEK 100 with continued healthy profitability</strong></h3>
<p><a href="http://probi.se/en/files/2013/01/Probi-Q4-2012-ENG.pdf" target="_blank">Read the full release here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2013/01/24/year-end-report-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Symrise and Probi sign joint research and development agreement</title>
		<link>http://probi.se/en/2012/12/20/symrise-and-probi-sign-joint-research-and-development-agreement/</link>
		<comments>http://probi.se/en/2012/12/20/symrise-and-probi-sign-joint-research-and-development-agreement/#comments</comments>
		<pubDate>Thu, 20 Dec 2012 07:08:18 +0000</pubDate>
		<dc:creator>sofie</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2351</guid>
		<description><![CDATA[2012-12-20 Symrise and Probi sign joint research and development agreement Probi has signed a research and development agreement with the German company Symrise, a leading manufacturer of flavours, fragrances, cosmetics and health ingredients. In response to a growing consumer interest, the companies have decided to jointly develop innovative probiotic products with documented health benefits. The [...]]]></description>
			<content:encoded><![CDATA[<p><strong>2012-12-20</strong></p>
<h3><strong>Symrise and Probi sign joint research and development agreement</strong></h3>
<p>Probi has signed a research and development agreement with the German company Symrise, a leading manufacturer of flavours, fragrances, cosmetics and health ingredients. In response to a growing consumer interest, the companies have decided to jointly develop innovative probiotic products with documented health benefits. The cooperation will initially focus on oral health.</p>
<p><a href="http://probi.se/en/files/2012/12/2012-12-Symrise-samarbete-eng.pdf" target="_blank">Read the full release here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2012/12/20/symrise-and-probi-sign-joint-research-and-development-agreement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Probiotic Business Development Alliance in North America</title>
		<link>http://probi.se/en/2012/12/11/probi-and-viva-5-corporation-form-probiotic-business-development-alliance-in-north-america/</link>
		<comments>http://probi.se/en/2012/12/11/probi-and-viva-5-corporation-form-probiotic-business-development-alliance-in-north-america/#comments</comments>
		<pubDate>Tue, 11 Dec 2012 07:49:16 +0000</pubDate>
		<dc:creator>ulrika</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2328</guid>
		<description><![CDATA[2012-12-11 Probi and Viva 5 Corporation form Probiotic Business Development Alliance in North America Probi has signed a business development agreement with Viva 5, a US probiotic specialist, granting them license rights within Consumer Healthcare for Probi Digestis® and Probi Defendum® in North America. Probi will work with Viva 5 to further strengthen its commercial [...]]]></description>
			<content:encoded><![CDATA[<p><strong>2012-12-11</strong></p>
<h3>Probi and Viva 5 Corporation form Probiotic Business Development Alliance in North America</h3>
<p>Probi has signed a business development agreement with Viva 5, a US probiotic specialist, granting them license rights within Consumer Healthcare for Probi Digestis<sup>®</sup> and Probi Defendum<sup>®</sup> in North America. Probi will work with Viva 5 to further strengthen its commercial position as well as the presence and consumer awareness of the Probi brand in the North American market place. Viva 5 and Probi are already engaged in commercial discussions with select US-based companies.</p>
<p><a href="http://probi.se/en/files/2012/12/2012-12-Probi-Viva-5-Eng.pdf" target="_blank">Read the full release here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2012/12/11/probi-and-viva-5-corporation-form-probiotic-business-development-alliance-in-north-america/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Results from Probi’s Clinical Studies</title>
		<link>http://probi.se/en/2012/11/29/results-from-probi%e2%80%99s-clinical-studies/</link>
		<comments>http://probi.se/en/2012/11/29/results-from-probi%e2%80%99s-clinical-studies/#comments</comments>
		<pubDate>Thu, 29 Nov 2012 07:47:00 +0000</pubDate>
		<dc:creator>sofie</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2288</guid>
		<description><![CDATA[2012-11-29 Results from Probi’s Clinical Studies in Immune and Gut Health The results from Probi’s two clinical studies conducted in 2012, one in immune health and one in gut health, are now available. Preliminary analyses of the data show that the results from the studies did not meet expectations. Probi will consequently not apply to [...]]]></description>
			<content:encoded><![CDATA[<p><strong>2012-11-29</strong></p>
<h3>Results from Probi’s Clinical Studies in Immune and Gut Health</h3>
<p>The results from Probi’s two clinical studies conducted in 2012, one in immune health and one in gut health, are now available. Preliminary analyses of the data show that the results from the studies did not meet expectations. Probi will consequently not apply to the European Food Safety Authority (EFSA) for health claims within the EU at this point.</p>
<p><a href="http://probi.se/en/files/2012/11/2012-11-Probi-Clinical-studies.pdf" target="_blank">Read the full release here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2012/11/29/results-from-probi%e2%80%99s-clinical-studies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nomination Committee at Probi AB</title>
		<link>http://probi.se/en/2012/10/24/nomination-committee-at-probi-ab/</link>
		<comments>http://probi.se/en/2012/10/24/nomination-committee-at-probi-ab/#comments</comments>
		<pubDate>Wed, 24 Oct 2012 06:33:22 +0000</pubDate>
		<dc:creator>sofie</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2258</guid>
		<description><![CDATA[2012-10-24 Nomination Committee at Probi AB Probi’s Nomination Committee prior to the 2013 Annual General Meeting comprises the following individuals: Heinz-Jürgen Bertram, Symrise Erik Sjöström, Skandia Bengt Jeppsson, Professor in the surgery unit, Lund University Reade the full release here]]></description>
			<content:encoded><![CDATA[<p><strong>2012-10-24</strong></p>
<h3>Nomination Committee at Probi AB</h3>
<p>Probi’s Nomination Committee prior to the 2013 Annual General Meeting comprises the following individuals:<br />
Heinz-Jürgen Bertram, Symrise<br />
Erik Sjöström, Skandia<br />
Bengt Jeppsson, Professor in the surgery unit, Lund University</p>
<p><a href="http://probi.se/en/files/2012/10/2012-10-Probi-Valberedning-eng.pdf" target="_blank">Reade the full release here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2012/10/24/nomination-committee-at-probi-ab/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interim Report January &#8211; September 2012</title>
		<link>http://probi.se/en/2012/10/18/interim-report-january-september-2012/</link>
		<comments>http://probi.se/en/2012/10/18/interim-report-january-september-2012/#comments</comments>
		<pubDate>Thu, 18 Oct 2012 09:14:00 +0000</pubDate>
		<dc:creator>sofie</dc:creator>
				<category><![CDATA[Okategoriserade]]></category>

		<guid isPermaLink="false">http://probi.se/en/?p=2252</guid>
		<description><![CDATA[2012-10-18 Full-year growth despite decline for ProViva Read the full release here]]></description>
			<content:encoded><![CDATA[<p><strong>2012-10-18</strong></p>
<h3><strong>Full-year growth despite decline for ProViva</strong></h3>
<p><a href="http://probi.se/en/files/2012/10/Probi-Q3-2012-eng.pdf" target="_blank">Read the full release here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://probi.se/en/2012/10/18/interim-report-january-september-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
